GlassScriptPhysician profile
Ujjwal Rastogi
NPI 1699169904
$13,684.13
in general payments reported to CMS, 2019-2025
30 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.55 · 2020: $1,410 · 2021: $1,625 · 2022: $2,319 · 2023: $4,957 · 2024: $1,705 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,531 · Food and Beverage: $2,712 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,531.04 |
| Food and Beverage | $2,711.73 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,610.61 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $2,308.75 | 2021-2025 | Mitraclip, Cardiomems, Diamondback Peripheral |
| Boston Scientific Corporation | $2,204.87 | 2020-2023 | Watchman Access System |
| Medtronic, INC. | $1,608.99 | 2021-2025 | Corevalve Evolut R, Abre |
| Cardiovascular Systems INC. | $927.10 | 2020-2023 | Diamondback Coronary |
| Abiomed | $922.60 | 2020-2023 | Impella |
| Silk Road Medical, INC. | $375.15 | 2022-2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Philips North America LLC | $366.67 | 2020-2021 | |
| Penumbra, INC. | $345.43 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $320.90 | 2020-2023 | Venclose Maven Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $225.09 | 2020-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $200.61 | 2021-2023 | Xarelto |
| Surmodics, INC. | $145.36 | 2022 | |
| Siemens Medical Solutions USA, INC. | $118.69 | 2024 | Acuson Sc2000 Diagnostic Ultrasound System |
| Pfizer INC. | $110.85 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $108.27 | 2020-2022 | |
| Inari Medical, INC. | $101.13 | 2021 | |
| Merck Sharp & Dohme LLC | $93.74 | 2022-2023 | Verquvo |
| Cardiva Medical, INC. | $90.04 | 2021 | |
| Medtronic Vascular, INC. | $86.55 | 2019 | |
| Astellas Pharma US INC | $75.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $72.67 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.30 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.47 | 2021-2023 | Jardiance |
| Cvrx, INC. | $45.41 | 2023 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $27.92 | 2023 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $20.74 | 2022 | |
| Amarin Pharma, INC. | $20.57 | 2022 | |
| Esperion Therapeutics, INC. | $17.95 | 2021 | |
| Amgen INC. | $15.70 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ujjwal Rastogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.